Nos publications
Enquête sur l'attente des médecins concernant l'onconéphrologie
- Delaye M, Try M, Rousseau A, Lafargue MC, Saillant A, Bainaud M, Andreani M, Rozenblat D, Campedel L, Corbaux P, Isnard-Bagnis C. Onco-nephrology: Physicians' Expectations About a New Subspecialty. J Cancer Educ. 2022 Jul 15. doi: 10.1007/s13187-022-02201-8. Epub ahead of print. PMID: 35840858. https://pubmed.ncbi.nlm.nih.gov/35840858/
Développement de l'onconéphrologie en France
- Delaye M, Try M, Campedel L, Corbaux P, Rousseau A, Isnard Bagnis C. Development and organization of onco-nephrology in France, comment on "The path toward the creation of the American Society of Onco-Nephrology (ASON)." Journal of Onco-Nephrology. June 2022. doi:10.1177/23993693221106490 https://journals.sagepub.com/doi/full/10.1177/23993693221106490
Numéro spécial Onconéphrologie de la revue du praticien
- Isnard-Bagnis C. Onconéphrologie : 10 messages clés [Onconéphrologie: 10 key messages]. Rev Prat. 2021 Feb;71(2):223. French. PMID: 34160988. https://pubmed.ncbi.nlm.nih.gov/34160988/
- Rafat C, Garcia H, Grangé S. Insuffisance rénale aiguë et traitement du cancer [Acute renal failure and cancer treatment]. Rev Prat. 2021 Feb;71(2):216-222. French. PMID: 34160987. https://pubmed.ncbi.nlm.nih.gov/34160987/
- Try M, Cohen A, Ederhy S. Thérapies ciblées et hypertension artérielle [Targeted therapies and high blood pressure]. Rev Prat. 2021 Feb;71(2):212-215. French. PMID: 34160986. https://pubmed.ncbi.nlm.nih.gov/34160986/
- Delaye M, Zahr N, Isnard-Bagnis C, Gougis P, Campedel L. Fonction rénale et traitement du cancer : quels problèmes pour l'oncologue ? [Kidney function and cancer treatment: which problems for the oncologist?]. Rev Prat. 2021 Feb;71(2):206-211. French. PMID: 34160985. https://pubmed.ncbi.nlm.nih.gov/34160985/
- Rousseau A, Lafargue MC, Snard-Bagnis C, Campedel L, Sahali D, Gougis P, Hénique C. Insuffisance rénale et symptômes rénaux associés aux thérapies moléculaires ciblées en oncologie [Renal failure and renal symptoms associated with molecular targeted therapies in oncology]. Rev Prat. 2021 Feb;71(2):198-205. French. PMID: 34160984. https://pubmed.ncbi.nlm.nih.gov/34160984/
- Garcia H, Teuma C, Languille E. Toxicité rénale des anticancéreux [Renal toxicity of antineoplasic agents]. Rev Prat. 2021 Feb;71(2):193-197. French. PMID: 34160983. https://pubmed.ncbi.nlm.nih.gov/34160983/
- Isnard-Bagnis C. Épidémiologie et facteurs de risque d'atteinte rénale au cours d'une chimiothérapie [Epidemiology and risk factors for kidney damage during chemotherapy]. Rev Prat. 2021 Feb;71(2):190-192. French. PMID: 34160982. https://pubmed.ncbi.nlm.nih.gov/34160982/
Insuffisance rénale aiguë et inhibiteurs de checkpoints immunitaires :
Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPi-AKI Consortium Investigators. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 Oct;9(10):e003467. doi: 10.1136/jitc-2021-003467. PMID: 34625513; https://pubmed.ncbi.nlm.nih.gov/34625513/
Bibliographie utile :
Toxicité rénale des anticancéreux
- Radiation infra rouge pour diminuer les dommages vasculaires au cisplatine :
Chen CH, Chen MC, Hsu YH, Chou TC. Far-infrared radiation alleviates cisplatin-induced vascular damage and impaired circulation via activation of HIF-1α. Cancer Sci. 2022 Jun;113(6):2194-2206. doi: 10.1111/cas.15371. Epub 2022 Apr 20. PMID: 35411640; PMCID: PMC9207382. https://pubmed.ncbi.nlm.nih.gov/35411640/
- Nephropathie radique et MAT après Lutetium-PSMA :
Schäfer H, Mayr S, Büttner-Herold M, Knorr K, Steinhelfer L, Böger CA, Gschwend JE, Heemann U, Eiber M, Schmaderer C, Tauber R. Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture. Eur Urol. 2022 Jun 7:S0302-2838(22)02401-0. doi: 10.1016/j.eururo.2022.05.025. Epub ahead of print. PMID: 35688660. https://pubmed.ncbi.nlm.nih.gov/35688660/
- Matrine pour diminuter les lésions rénales du cisplatine :
Yuan L, Yang J, Li Y, Yuan L, Liu F, Yuan Y, Tang X. Matrine alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial dysfunction and inflammation via SIRT3/OPA1 pathway. J Cell Mol Med. 2022 Jul;26(13):3702-3715. doi: 10.1111/jcmm.17398. Epub 2022 Jun 1. PMID: 35650472; PMCID: PMC9258713. https://pubmed.ncbi.nlm.nih.gov/35650472/
- Mannitol pour réduire la néphrotoxicité du cisplatine :
Sainamthip P, Saichaemchan S, Satirapoj B, Prasongsook N. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial. JCO Glob Oncol. 2022 Mar;8:e2100275. doi: 10.1200/GO.21.00275. PMID: 35436142. https://pubmed.ncbi.nlm.nih.gov/35436142/
- Prise de décision de continuer un anti angiogénique :
Nakamura M, Funakoshi T, Kataoka S, Horimatsu T, Nishikawa Y, Matsubara T, Mizukami T, Goto T, Tsuchihashi K, Baba E, Tsumura T, Mihara Y, Hamaguchi T, Yanagita M, Muto M. Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study). BMC Cancer. 2022 May 7;22(1):515. doi: 10.1186/s12885-022-09611-3. PMID: 35525917; PMCID: PMC9080145. https://pubmed.ncbi.nlm.nih.gov/35525917/
- Autogreffe chez les patients avec un myélome et une insuffisance rénale :
Lazana I, Floro L, Christmas T, Shah S, Bramham K, Cuthill K, Bassett P, Schey S, Kazmi M, Potter V, Pagliuca A, Streetly M, Benjamin R. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. Bone Marrow Transplant. 2022 Jun;57(6):959-965. doi: 10.1038/s41409-022-01657-y. Epub 2022 Apr 12. PMID: 35413986; PMCID: PMC9200631. https://pubmed.ncbi.nlm.nih.gov/35413986/
- Recharge en magnesium avant injection de cisplatine :
Suppadungsuk S, Phitakwatchara W, Reungwetwattana T, Pathumarak A, Phakdeekitcharoen B, Kitiyakara C, Srisuwarn P, Davenport A, Nongnuch A. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study). ESMO Open. 2022 Feb;7(1):100351. doi: 10.1016/j.esmoop.2021.100351. Epub 2021 Dec 23. PMID: 34953401; PMCID: PMC8717436. https://pubmed.ncbi.nlm.nih.gov/34953401/
Gestion de l'insuffisance rénale
- Evaluation des types de désobstruction urinaire : chirurgicale ou radiologique :
Pietropaolo A, Seoane LM, Abadia AA, Geraghty R, Kallidonis P, Tailly T, Modi S, Tzelves L, Sarica K, Gozen A, Emiliani E, Sener E, Rai BP, Hameed ZBM, Liatsikos E, Rivas JG, Skolarikos A, Somani BK. Emergency upper urinary tract decompression: double-J stent or nephrostomy? A European YAU/ESUT/EULIS/BSIR survey among urologists and radiologists. World J Urol. 2022 Jul;40(7):1629-1636. doi: 10.1007/s00345-022-03979-4. Epub 2022 Mar 14. PMID: 35286423; PMCID: PMC8918906. https://pubmed.ncbi.nlm.nih.gov/35286423/
- Estimation du DGF avec creatinine et cystatine C chez les patients avec un cancer :
Costa E Silva VT, Gil LA Jr, Inker LA, Caires RA, Costalonga E, Coura-Filho G, Sapienza MT, Castro G Jr, Estevez-Diz MD, Zanetta DMT, Antonângelo L, Marçal L, Tighiouart H, Miao S, Mathew P, Levey AS, Burdmann EA. A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int. 2022 Mar;101(3):607-614. doi: 10.1016/j.kint.2021.12.010. Epub 2022 Jan 12. PMID: 35032521. https://pubmed.ncbi.nlm.nih.gov/35032521/
Epidémiologie
- Insuffisance rénale chronique en Europe de l'Est :
Ciorcan M, Chisavu L, Mihaescu A, Gadalean F, Bob FR, Negru S, Schiller OM, Grosu ID, Marc L, Chisavu F, Dragota Pascota R, Apostol A, Ivan V, Schiller A. Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe. PLoS One. 2022 Jun 9;17(6):e0265930. doi: 10.1371/journal.pone.0265930. PMID: 35679539; PMCID: PMC9183451. https://pubmed.ncbi.nlm.nih.gov/35679539/
- Facteurs prédictifs d'IRA chez les patients autogreffés pour amylose AL :
Nader R, Zhen A, Angel-Korman A, Pavlovich SS, Pogrebinsky A, Doros G, Menn-Josephy H, Stern L, Sanchorawala V, Havasi A. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrol Dial Transplant. 2022 Jun 23;37(7):1281-1288. doi: 10.1093/ndt/gfab189. PMID: 34043009. https://pubmed.ncbi.nlm.nih.gov/34043009/
- Devenir des greffés rénaux américains avec un myélome ou une amylose :
Ng JH, Izard S, Murakami N, Jhaveri KD, Sharma A, Nair V. Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the US. Nephrol Dial Transplant. 2022 Jun 10:gfac196. doi: 10.1093/ndt/gfac196. Epub ahead of print. PMID: 35687020. https://pubmed.ncbi.nlm.nih.gov/35687020/
- Facteurs de risque d'IRA chez les patients avec une hémopathie :
Travassos PNC, de Barros Silva PG, Freitas MO, Braga MDM, Duarte FB, de Oliveira Maia JK, Pitombeira H, de Sousa JH, Alves APNN. Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment. Support Care Cancer. 2022 May 21. doi: 10.1007/s00520-022-07159-3. Epub ahead of print. PMID: 35596773. https://pubmed.ncbi.nlm.nih.gov/35596773/
- Problèmes urinaires chez les femmes avec un cancer de l'endomètre :
Anderson C, Olshan AF, Park J, Bae-Jump VL, Brewster WR, Lund JL, Nichols HB. Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1368-1375. doi: 10.1158/1055-9965.EPI-22-0236. PMID: 35545287. https://pubmed.ncbi.nlm.nih.gov/35545287/
- Survie du greffon chez les transplantés atteints de myélome :
Dykes K, Desale S, Javaid B, Miatlovich K, Kessler C. A New Reality for Multiple Myeloma Renal Failure: US Data Report on Kidney Transplant Outcomes. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e314-e320. doi: 10.1016/j.clml.2021.11.002. Epub 2021 Nov 11. PMID: 34872880. https://pubmed.ncbi.nlm.nih.gov/34872880/
- Risque et mortalité par cancer chez les patients insuffisants rénaux chroniques :
Kitchlu A, Reid J, Jeyakumar N, Dixon SN, Munoz AM, Silver SA, Booth CM, Chan CTM, Garg AX, Amir E, Kim SJ, Wald R. Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. Am J Kidney Dis. 2022 Apr 8:S0272-6386(22)00582-0. doi: 10.1053/j.ajkd.2022.02.020. Epub ahead of print. PMID: 35405208. https://pubmed.ncbi.nlm.nih.gov/35405208/
- Syndrome de lyse tumoral chez les patients de soins intensifs nécessitant une chimiothérapie :
Abdel-Nabey M, Chaba A, Serre J, Lengliné E, Azoulay E, Darmon M, Zafrani L. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. Ann Intensive Care. 2022 Feb 15;12(1):15. doi: 10.1186/s13613-022-00990-1. PMID: 35166948; PMCID: PMC8847484. https://pubmed.ncbi.nlm.nih.gov/35166948/#affiliation-4